INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1001, 22554, 'Ketoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1002, 22555, 'Ketoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1003, 22557, 'Ketoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1004, 25307, 'Ketoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1005, 25308, 'Ketoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1006, 25309, 'Ketoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1007, 25310, 'Ketoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1008, 25311, 'Ketoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1009, 28285, 'Ketoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1010, 728, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1011, 2676, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1012, 4068, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1013, 12338, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1014, 13694, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1015, 14137, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1016, 14138, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1017, 14139, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1018, 14140, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1019, 14141, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1020, 14142, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1021, 21519, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1022, 21520, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1023, 21521, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1024, 21522, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1025, 21523, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1026, 21524, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1027, 30778, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1028, 30779, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1029, 30780, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1030, 30782, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1031, 32258, 'Lacosamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1032, 728, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1033, 2676, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1034, 4068, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1035, 12338, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1036, 13694, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1037, 14137, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1038, 14138, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1039, 14139, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1040, 14140, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1041, 14141, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1042, 14142, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1043, 21519, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1044, 21520, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1045, 21521, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1046, 21522, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1047, 21523, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1048, 21524, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1049, 30778, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1050, 30779, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1051, 30780, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1052, 30782, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1053, 32258, 'Lacosamide', 'Cardiovascular Diseases', 'Dose dependent prolongation in PR interval has been observed with the use of lacosamide.  This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval.  An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1054, 728, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1055, 2676, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1056, 4068, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1057, 12338, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1058, 13694, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1059, 14137, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1060, 14138, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1061, 14139, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1062, 14140, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1063, 14141, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1064, 14142, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1065, 21519, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1066, 21520, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1067, 21521, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1068, 21522, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1069, 21523, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1070, 21524, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1071, 30778, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1072, 30779, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1073, 30780, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1074, 30782, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1075, 32258, 'Lacosamide', 'Hepatic Insufficiency', 'Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration.  A maximum dose of 300 mg/day is recommended for these patients.  Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1076, 728, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1077, 2676, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1078, 4068, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1079, 12338, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1080, 13694, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1081, 14137, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1082, 14138, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1083, 14139, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1084, 14140, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1085, 14141, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1086, 14142, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1087, 21519, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1088, 21520, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1089, 21521, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1090, 21522, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1091, 21523, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1092, 21524, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1093, 30778, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1094, 30779, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1095, 30780, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1096, 30782, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1097, 32258, 'Lacosamide', 'Kidney Diseases', 'A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease.  Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure.  Dose titration should be done with caution in all renally impaired patients.', '2', '"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1098, 16480, 'Lactic acid', 'Water-Electrolyte Imbalance', 'Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure.  Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.', '3', '"Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1099, 19061, 'Lactic acid', 'Water-Electrolyte Imbalance', 'Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure.  Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.', '3', '"Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1100, 16480, 'Lactic acid', 'Acidosis, Lactic', 'Lactate metabolism results in production of bicarbonate.  Bicarbonate generation is impaired in patients with compromised liver function and/or disorders that decrease tissue perfusion and increase anoxia.  Therapy with sodium lactate should not be used in conditions in which lactate levels are increased (e.g., shock, congestive heart failure, respiratory alkalosis) or in which utilization of lactate is diminished (e.g., anoxia, beriberi).  Sodium lactate is not for use in the treatment of lactic acidosis.', '3', '"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1101, 19061, 'Lactic acid', 'Acidosis, Lactic', 'Lactate metabolism results in production of bicarbonate.  Bicarbonate generation is impaired in patients with compromised liver function and/or disorders that decrease tissue perfusion and increase anoxia.  Therapy with sodium lactate should not be used in conditions in which lactate levels are increased (e.g., shock, congestive heart failure, respiratory alkalosis) or in which utilization of lactate is diminished (e.g., anoxia, beriberi).  Sodium lactate is not for use in the treatment of lactic acidosis.', '3', '"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1102, 16480, 'Lactic acid', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Tham (tromethamine)." Abbott Pharmaceutical  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1103, 19061, 'Lactic acid', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Tham (tromethamine)." Abbott Pharmaceutical  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1104, 4696, 'Labetalol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1105, 7023, 'Labetalol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1106, 21511, 'Labetalol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1107, 21513, 'Labetalol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1108, 4696, 'Labetalol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Acupress (carteolol ophthalmic)." Otsuka American Pharmaceuticals Inc, Rockville, MD.|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1109, 7023, 'Labetalol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Acupress (carteolol ophthalmic)." Otsuka American Pharmaceuticals Inc, Rockville, MD.|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1110, 21511, 'Labetalol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Acupress (carteolol ophthalmic)." Otsuka American Pharmaceuticals Inc, Rockville, MD.|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1111, 21513, 'Labetalol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Acupress (carteolol ophthalmic)." Otsuka American Pharmaceuticals Inc, Rockville, MD.|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1112, 4696, 'Labetalol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Lechat P, Jaillon P, Fontaine ML, Chanton E, Mesenge C, Gagey S, Guillardeau A, Dussous V "A randomized trial of beta-blockade in heart failure - the cardiac insufficiency bisoprolol study (CIBIS)." Circulation 90 (1994):  1765-73|Maisel AS "Beneficial effects of metoprolol treatment in congestive heart failure - reversal of sympathetic-induced alterations of immunologic function." Circulation 90 (1994):  1774-80|Persson H, Rythenalder E, Melcher A, Erhardt L "Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol." Br Heart J 74 (1995):  140-8|Kelly DT "Carvedilol in heart failure." Cardiology 82 Suppl 3 (1993):  45-9|Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR "Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study." J Am Coll Cardiol 25 (1995):  1225-31|Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. "Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure." Circulation 92 (1995):  1499-506|Australia-New Zealand Heart Failure Research Collaborative Group. "Effects of carvedilol, a vasodilator-B-blocker, in patients with congestive heart failure due to ischemic heart disease." Circulation 92 (1995):  212-8|Kalman J, Buchholz C, Steinmetz M, Courtney M, Gass A, Lansman S, Kukin ML "Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation." J Heart Lung Transplant 14 (1995):  1212-7|Adams KF Jr "Current perspectives on B-receptor antagonists in the treatment of symptomatic ventricular dysfunction." Pharmacotherapy 16(2 Pt 2) (1996):  69-77|Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure." N Engl J Med 334 (1996):  1349-55|Persson SV, Erhardt L "Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol: echocardiographic results from the Metoprolol and..." Eur Heart J 17 (1996):  741-9|Cleland JGF, Swedberg K "Carvedilol for heart failure, with care." Lancet 347 (1996):  1199-201|Moye LA, Abernethy D "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318|Von Olshausen K, Pop T, Berger J "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318-20|Packer M, Cohn JN, Colucci WS "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1310-20|Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackne "Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure." Circulation 94 (1996):  2800-6|Macmahon S, Sharpe N, Doughty R, Krum H, Tonkin A, Trotter A, Burton R, Garrett J, Lane G, Owensby D, Ryan J, Shepherd J, Sing "Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease." Lancet 349 (1997):  375-80|Bristow MR, Gilbert EM, Abraham WT, et al. "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators." Circulation 94 (1996):  2807-16|Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D "Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial Prospective Randomized Evaluation of Carvedilol on Symptoms an Exercise." Circulation 94 (1996):  2793-9|Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N "Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-Ne Zealand Heart Failure Research Collaborative Group." J Am Coll Cardiol 29 (1997):  1060-6|Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP "Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials." Circulation 98 (1998):  1184-91|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|CIBIS-II Investigators and Committees. "The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial." Lancet 353 (1999):  9-13|Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ "Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure." J Am Coll Cardiol 33 (1999):  924-31|Hjalmarson A, Goldstein S, Fagerberg B, et al. "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)." JAMA 283 (2000):  1295-302|Phillips KA, Shlipak MG, Coxson P, et al. "Health and economic benefits of increased B-blocker use following myocardial infarction." JAMA 284 (2000):  2748-54|Hart SM "Influence of B-blockers on mortality in chronic heart failure." Ann Pharmacother 34 (2000):  1440-51|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1113, 7023, 'Labetalol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Lechat P, Jaillon P, Fontaine ML, Chanton E, Mesenge C, Gagey S, Guillardeau A, Dussous V "A randomized trial of beta-blockade in heart failure - the cardiac insufficiency bisoprolol study (CIBIS)." Circulation 90 (1994):  1765-73|Maisel AS "Beneficial effects of metoprolol treatment in congestive heart failure - reversal of sympathetic-induced alterations of immunologic function." Circulation 90 (1994):  1774-80|Persson H, Rythenalder E, Melcher A, Erhardt L "Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol." Br Heart J 74 (1995):  140-8|Kelly DT "Carvedilol in heart failure." Cardiology 82 Suppl 3 (1993):  45-9|Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR "Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study." J Am Coll Cardiol 25 (1995):  1225-31|Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. "Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure." Circulation 92 (1995):  1499-506|Australia-New Zealand Heart Failure Research Collaborative Group. "Effects of carvedilol, a vasodilator-B-blocker, in patients with congestive heart failure due to ischemic heart disease." Circulation 92 (1995):  212-8|Kalman J, Buchholz C, Steinmetz M, Courtney M, Gass A, Lansman S, Kukin ML "Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation." J Heart Lung Transplant 14 (1995):  1212-7|Adams KF Jr "Current perspectives on B-receptor antagonists in the treatment of symptomatic ventricular dysfunction." Pharmacotherapy 16(2 Pt 2) (1996):  69-77|Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure." N Engl J Med 334 (1996):  1349-55|Persson SV, Erhardt L "Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol: echocardiographic results from the Metoprolol and..." Eur Heart J 17 (1996):  741-9|Cleland JGF, Swedberg K "Carvedilol for heart failure, with care." Lancet 347 (1996):  1199-201|Moye LA, Abernethy D "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318|Von Olshausen K, Pop T, Berger J "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318-20|Packer M, Cohn JN, Colucci WS "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1310-20|Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackne "Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure." Circulation 94 (1996):  2800-6|Macmahon S, Sharpe N, Doughty R, Krum H, Tonkin A, Trotter A, Burton R, Garrett J, Lane G, Owensby D, Ryan J, Shepherd J, Sing "Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease." Lancet 349 (1997):  375-80|Bristow MR, Gilbert EM, Abraham WT, et al. "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators." Circulation 94 (1996):  2807-16|Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D "Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial Prospective Randomized Evaluation of Carvedilol on Symptoms an Exercise." Circulation 94 (1996):  2793-9|Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N "Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-Ne Zealand Heart Failure Research Collaborative Group." J Am Coll Cardiol 29 (1997):  1060-6|Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP "Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials." Circulation 98 (1998):  1184-91|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|CIBIS-II Investigators and Committees. "The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial." Lancet 353 (1999):  9-13|Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ "Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure." J Am Coll Cardiol 33 (1999):  924-31|Hjalmarson A, Goldstein S, Fagerberg B, et al. "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)." JAMA 283 (2000):  1295-302|Phillips KA, Shlipak MG, Coxson P, et al. "Health and economic benefits of increased B-blocker use following myocardial infarction." JAMA 284 (2000):  2748-54|Hart SM "Influence of B-blockers on mortality in chronic heart failure." Ann Pharmacother 34 (2000):  1440-51|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1114, 21511, 'Labetalol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Lechat P, Jaillon P, Fontaine ML, Chanton E, Mesenge C, Gagey S, Guillardeau A, Dussous V "A randomized trial of beta-blockade in heart failure - the cardiac insufficiency bisoprolol study (CIBIS)." Circulation 90 (1994):  1765-73|Maisel AS "Beneficial effects of metoprolol treatment in congestive heart failure - reversal of sympathetic-induced alterations of immunologic function." Circulation 90 (1994):  1774-80|Persson H, Rythenalder E, Melcher A, Erhardt L "Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol." Br Heart J 74 (1995):  140-8|Kelly DT "Carvedilol in heart failure." Cardiology 82 Suppl 3 (1993):  45-9|Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR "Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study." J Am Coll Cardiol 25 (1995):  1225-31|Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. "Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure." Circulation 92 (1995):  1499-506|Australia-New Zealand Heart Failure Research Collaborative Group. "Effects of carvedilol, a vasodilator-B-blocker, in patients with congestive heart failure due to ischemic heart disease." Circulation 92 (1995):  212-8|Kalman J, Buchholz C, Steinmetz M, Courtney M, Gass A, Lansman S, Kukin ML "Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation." J Heart Lung Transplant 14 (1995):  1212-7|Adams KF Jr "Current perspectives on B-receptor antagonists in the treatment of symptomatic ventricular dysfunction." Pharmacotherapy 16(2 Pt 2) (1996):  69-77|Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure." N Engl J Med 334 (1996):  1349-55|Persson SV, Erhardt L "Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol: echocardiographic results from the Metoprolol and..." Eur Heart J 17 (1996):  741-9|Cleland JGF, Swedberg K "Carvedilol for heart failure, with care." Lancet 347 (1996):  1199-201|Moye LA, Abernethy D "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318|Von Olshausen K, Pop T, Berger J "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318-20|Packer M, Cohn JN, Colucci WS "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1310-20|Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackne "Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure." Circulation 94 (1996):  2800-6|Macmahon S, Sharpe N, Doughty R, Krum H, Tonkin A, Trotter A, Burton R, Garrett J, Lane G, Owensby D, Ryan J, Shepherd J, Sing "Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease." Lancet 349 (1997):  375-80|Bristow MR, Gilbert EM, Abraham WT, et al. "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators." Circulation 94 (1996):  2807-16|Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D "Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial Prospective Randomized Evaluation of Carvedilol on Symptoms an Exercise." Circulation 94 (1996):  2793-9|Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N "Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-Ne Zealand Heart Failure Research Collaborative Group." J Am Coll Cardiol 29 (1997):  1060-6|Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP "Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials." Circulation 98 (1998):  1184-91|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|CIBIS-II Investigators and Committees. "The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial." Lancet 353 (1999):  9-13|Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ "Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure." J Am Coll Cardiol 33 (1999):  924-31|Hjalmarson A, Goldstein S, Fagerberg B, et al. "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)." JAMA 283 (2000):  1295-302|Phillips KA, Shlipak MG, Coxson P, et al. "Health and economic benefits of increased B-blocker use following myocardial infarction." JAMA 284 (2000):  2748-54|Hart SM "Influence of B-blockers on mortality in chronic heart failure." Ann Pharmacother 34 (2000):  1440-51|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1115, 21513, 'Labetalol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Lechat P, Jaillon P, Fontaine ML, Chanton E, Mesenge C, Gagey S, Guillardeau A, Dussous V "A randomized trial of beta-blockade in heart failure - the cardiac insufficiency bisoprolol study (CIBIS)." Circulation 90 (1994):  1765-73|Maisel AS "Beneficial effects of metoprolol treatment in congestive heart failure - reversal of sympathetic-induced alterations of immunologic function." Circulation 90 (1994):  1774-80|Persson H, Rythenalder E, Melcher A, Erhardt L "Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol." Br Heart J 74 (1995):  140-8|Kelly DT "Carvedilol in heart failure." Cardiology 82 Suppl 3 (1993):  45-9|Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR "Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study." J Am Coll Cardiol 25 (1995):  1225-31|Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. "Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure." Circulation 92 (1995):  1499-506|Australia-New Zealand Heart Failure Research Collaborative Group. "Effects of carvedilol, a vasodilator-B-blocker, in patients with congestive heart failure due to ischemic heart disease." Circulation 92 (1995):  212-8|Kalman J, Buchholz C, Steinmetz M, Courtney M, Gass A, Lansman S, Kukin ML "Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation." J Heart Lung Transplant 14 (1995):  1212-7|Adams KF Jr "Current perspectives on B-receptor antagonists in the treatment of symptomatic ventricular dysfunction." Pharmacotherapy 16(2 Pt 2) (1996):  69-77|Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure." N Engl J Med 334 (1996):  1349-55|Persson SV, Erhardt L "Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol: echocardiographic results from the Metoprolol and..." Eur Heart J 17 (1996):  741-9|Cleland JGF, Swedberg K "Carvedilol for heart failure, with care." Lancet 347 (1996):  1199-201|Moye LA, Abernethy D "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318|Von Olshausen K, Pop T, Berger J "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318-20|Packer M, Cohn JN, Colucci WS "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1310-20|Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackne "Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure." Circulation 94 (1996):  2800-6|Macmahon S, Sharpe N, Doughty R, Krum H, Tonkin A, Trotter A, Burton R, Garrett J, Lane G, Owensby D, Ryan J, Shepherd J, Sing "Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease." Lancet 349 (1997):  375-80|Bristow MR, Gilbert EM, Abraham WT, et al. "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators." Circulation 94 (1996):  2807-16|Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D "Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial Prospective Randomized Evaluation of Carvedilol on Symptoms an Exercise." Circulation 94 (1996):  2793-9|Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N "Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-Ne Zealand Heart Failure Research Collaborative Group." J Am Coll Cardiol 29 (1997):  1060-6|Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP "Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials." Circulation 98 (1998):  1184-91|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|CIBIS-II Investigators and Committees. "The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial." Lancet 353 (1999):  9-13|Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ "Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure." J Am Coll Cardiol 33 (1999):  924-31|Hjalmarson A, Goldstein S, Fagerberg B, et al. "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)." JAMA 283 (2000):  1295-302|Phillips KA, Shlipak MG, Coxson P, et al. "Health and economic benefits of increased B-blocker use following myocardial infarction." JAMA 284 (2000):  2748-54|Hart SM "Influence of B-blockers on mortality in chronic heart failure." Ann Pharmacother 34 (2000):  1440-51|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1116, 4696, 'Labetalol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1117, 7023, 'Labetalol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1118, 21511, 'Labetalol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1119, 21513, 'Labetalol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1120, 4696, 'Labetalol', 'Diseases requiring hemodialysis', 'Therapy with beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in patients requiring hemodialysis.  When given after dialysis, hemodynamic stability should be established prior to drug administration to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Deetjen A, Heidland A, Pangerl A, Meyer-Sabellek W, Schaefer RM "Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients." Clin Nephrol 43 (1995):  47-52|Miki S, Masumura H, Kaifu Y, Yuasa S "Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s62-8|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1121, 7023, 'Labetalol', 'Diseases requiring hemodialysis', 'Therapy with beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in patients requiring hemodialysis.  When given after dialysis, hemodynamic stability should be established prior to drug administration to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Deetjen A, Heidland A, Pangerl A, Meyer-Sabellek W, Schaefer RM "Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients." Clin Nephrol 43 (1995):  47-52|Miki S, Masumura H, Kaifu Y, Yuasa S "Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s62-8|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1122, 21511, 'Labetalol', 'Diseases requiring hemodialysis', 'Therapy with beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in patients requiring hemodialysis.  When given after dialysis, hemodynamic stability should be established prior to drug administration to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Deetjen A, Heidland A, Pangerl A, Meyer-Sabellek W, Schaefer RM "Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients." Clin Nephrol 43 (1995):  47-52|Miki S, Masumura H, Kaifu Y, Yuasa S "Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s62-8|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1123, 21513, 'Labetalol', 'Diseases requiring hemodialysis', 'Therapy with beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in patients requiring hemodialysis.  When given after dialysis, hemodynamic stability should be established prior to drug administration to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Deetjen A, Heidland A, Pangerl A, Meyer-Sabellek W, Schaefer RM "Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients." Clin Nephrol 43 (1995):  47-52|Miki S, Masumura H, Kaifu Y, Yuasa S "Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s62-8|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1124, 4696, 'Labetalol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1125, 7023, 'Labetalol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1126, 21511, 'Labetalol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1127, 21513, 'Labetalol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1128, 4696, 'Labetalol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'Miller RR, Olson HG, Amsterdam EA, Mason DT "Propranolol-withdrawal rebound phenomenon: exacerbation of coronary events after abrupt cessation of antianginal therapy." N Engl J Med 293 (1975):  416-8|Rangno RE, Langlois S "Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol." Am Heart J 104 (1982):  473-8|Szecsi E, Kohlschutter S, Schiess W, Lang E "Abrupt withdrawal of pindolol or metoprolol after chronic therapy." Br J Clin Pharmacol 13 (1982):  s353-7|Walden RJ, Hernandez J, Yu Y, et al. "Withdrawal of beta-blocking drugs." Am Heart J 104 (1982):  515-20|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1129, 7023, 'Labetalol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'Miller RR, Olson HG, Amsterdam EA, Mason DT "Propranolol-withdrawal rebound phenomenon: exacerbation of coronary events after abrupt cessation of antianginal therapy." N Engl J Med 293 (1975):  416-8|Rangno RE, Langlois S "Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol." Am Heart J 104 (1982):  473-8|Szecsi E, Kohlschutter S, Schiess W, Lang E "Abrupt withdrawal of pindolol or metoprolol after chronic therapy." Br J Clin Pharmacol 13 (1982):  s353-7|Walden RJ, Hernandez J, Yu Y, et al. "Withdrawal of beta-blocking drugs." Am Heart J 104 (1982):  515-20|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1130, 21511, 'Labetalol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'Miller RR, Olson HG, Amsterdam EA, Mason DT "Propranolol-withdrawal rebound phenomenon: exacerbation of coronary events after abrupt cessation of antianginal therapy." N Engl J Med 293 (1975):  416-8|Rangno RE, Langlois S "Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol." Am Heart J 104 (1982):  473-8|Szecsi E, Kohlschutter S, Schiess W, Lang E "Abrupt withdrawal of pindolol or metoprolol after chronic therapy." Br J Clin Pharmacol 13 (1982):  s353-7|Walden RJ, Hernandez J, Yu Y, et al. "Withdrawal of beta-blocking drugs." Am Heart J 104 (1982):  515-20|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1131, 21513, 'Labetalol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'Miller RR, Olson HG, Amsterdam EA, Mason DT "Propranolol-withdrawal rebound phenomenon: exacerbation of coronary events after abrupt cessation of antianginal therapy." N Engl J Med 293 (1975):  416-8|Rangno RE, Langlois S "Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol." Am Heart J 104 (1982):  473-8|Szecsi E, Kohlschutter S, Schiess W, Lang E "Abrupt withdrawal of pindolol or metoprolol after chronic therapy." Br J Clin Pharmacol 13 (1982):  s353-7|Walden RJ, Hernandez J, Yu Y, et al. "Withdrawal of beta-blocking drugs." Am Heart J 104 (1982):  515-20|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1132, 4696, 'Labetalol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1133, 7023, 'Labetalol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1134, 21511, 'Labetalol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1135, 21513, 'Labetalol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1136, 4696, 'Labetalol', 'Liver Diseases', 'Labetalol is primarily metabolized by the liver.  Although its elimination half-life is not altered in patients with impaired hepatic function, the oral bioavailability is greater due to decreased first-pass metabolism.  Dosage adjustments may be necessary for patients with liver disease, particularly when labetalol is administered orally.  In addition, the use of labetalol has been rarely associated with hepatic injury, including cholestatic jaundice, hepatitis, and hepatic necrosis.  Therapy with labetalol should be administered cautiously in patients with a current or past history of liver disease.  Routine monitoring of liver function tests is recommended.', '3', 'Martin LE, Hopkins R, Bland R "Metabolism of labetalol by animals and man." Br J Clin Pharmacol 3 (4 Suppl) (1976):  695-710|Homeida M, Jackson L, Roberts CJ "Decreased first-pass metabolism of labetalol in chronic liver disease." Br Med J 2 (1978):  1048-50|Clark JA, Zimmerman HJ, Tanner LA "Labetalol hepatotoxicity." Ann Intern Med 113 (1990):  210-3|Douglas DD, Yang RD, Jensen P, Thiele DL "Fatal labetalol-induced hepatic injury." Am J Med 87 (1989):  235-6|Stumpf J "Fatal hepatotoxicity induced by hydralazine or labetalol." Pharmacotherapy 11 (1991):  415-8|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1137, 7023, 'Labetalol', 'Liver Diseases', 'Labetalol is primarily metabolized by the liver.  Although its elimination half-life is not altered in patients with impaired hepatic function, the oral bioavailability is greater due to decreased first-pass metabolism.  Dosage adjustments may be necessary for patients with liver disease, particularly when labetalol is administered orally.  In addition, the use of labetalol has been rarely associated with hepatic injury, including cholestatic jaundice, hepatitis, and hepatic necrosis.  Therapy with labetalol should be administered cautiously in patients with a current or past history of liver disease.  Routine monitoring of liver function tests is recommended.', '3', 'Martin LE, Hopkins R, Bland R "Metabolism of labetalol by animals and man." Br J Clin Pharmacol 3 (4 Suppl) (1976):  695-710|Homeida M, Jackson L, Roberts CJ "Decreased first-pass metabolism of labetalol in chronic liver disease." Br Med J 2 (1978):  1048-50|Clark JA, Zimmerman HJ, Tanner LA "Labetalol hepatotoxicity." Ann Intern Med 113 (1990):  210-3|Douglas DD, Yang RD, Jensen P, Thiele DL "Fatal labetalol-induced hepatic injury." Am J Med 87 (1989):  235-6|Stumpf J "Fatal hepatotoxicity induced by hydralazine or labetalol." Pharmacotherapy 11 (1991):  415-8|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1138, 21511, 'Labetalol', 'Liver Diseases', 'Labetalol is primarily metabolized by the liver.  Although its elimination half-life is not altered in patients with impaired hepatic function, the oral bioavailability is greater due to decreased first-pass metabolism.  Dosage adjustments may be necessary for patients with liver disease, particularly when labetalol is administered orally.  In addition, the use of labetalol has been rarely associated with hepatic injury, including cholestatic jaundice, hepatitis, and hepatic necrosis.  Therapy with labetalol should be administered cautiously in patients with a current or past history of liver disease.  Routine monitoring of liver function tests is recommended.', '3', 'Martin LE, Hopkins R, Bland R "Metabolism of labetalol by animals and man." Br J Clin Pharmacol 3 (4 Suppl) (1976):  695-710|Homeida M, Jackson L, Roberts CJ "Decreased first-pass metabolism of labetalol in chronic liver disease." Br Med J 2 (1978):  1048-50|Clark JA, Zimmerman HJ, Tanner LA "Labetalol hepatotoxicity." Ann Intern Med 113 (1990):  210-3|Douglas DD, Yang RD, Jensen P, Thiele DL "Fatal labetalol-induced hepatic injury." Am J Med 87 (1989):  235-6|Stumpf J "Fatal hepatotoxicity induced by hydralazine or labetalol." Pharmacotherapy 11 (1991):  415-8|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1139, 21513, 'Labetalol', 'Liver Diseases', 'Labetalol is primarily metabolized by the liver.  Although its elimination half-life is not altered in patients with impaired hepatic function, the oral bioavailability is greater due to decreased first-pass metabolism.  Dosage adjustments may be necessary for patients with liver disease, particularly when labetalol is administered orally.  In addition, the use of labetalol has been rarely associated with hepatic injury, including cholestatic jaundice, hepatitis, and hepatic necrosis.  Therapy with labetalol should be administered cautiously in patients with a current or past history of liver disease.  Routine monitoring of liver function tests is recommended.', '3', 'Martin LE, Hopkins R, Bland R "Metabolism of labetalol by animals and man." Br J Clin Pharmacol 3 (4 Suppl) (1976):  695-710|Homeida M, Jackson L, Roberts CJ "Decreased first-pass metabolism of labetalol in chronic liver disease." Br Med J 2 (1978):  1048-50|Clark JA, Zimmerman HJ, Tanner LA "Labetalol hepatotoxicity." Ann Intern Med 113 (1990):  210-3|Douglas DD, Yang RD, Jensen P, Thiele DL "Fatal labetalol-induced hepatic injury." Am J Med 87 (1989):  235-6|Stumpf J "Fatal hepatotoxicity induced by hydralazine or labetalol." Pharmacotherapy 11 (1991):  415-8|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1140, 4696, 'Labetalol', 'Asthma', 'Some beta-adrenergic receptor blocking agents (i.e., non-cardioselective beta-blockers) are contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease.  In general, beta-adrenergic receptor blocking agents should not be used in patients with bronchospastic diseases.  Beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  If beta-blocker therapy is necessary in these patients, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer, but should be used with caution nonetheless.  Cardioselectivity is not absolute and can be lost with larger doses.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1141, 7023, 'Labetalol', 'Asthma', 'Some beta-adrenergic receptor blocking agents (i.e., non-cardioselective beta-blockers) are contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease.  In general, beta-adrenergic receptor blocking agents should not be used in patients with bronchospastic diseases.  Beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  If beta-blocker therapy is necessary in these patients, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer, but should be used with caution nonetheless.  Cardioselectivity is not absolute and can be lost with larger doses.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1142, 21511, 'Labetalol', 'Asthma', 'Some beta-adrenergic receptor blocking agents (i.e., non-cardioselective beta-blockers) are contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease.  In general, beta-adrenergic receptor blocking agents should not be used in patients with bronchospastic diseases.  Beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  If beta-blocker therapy is necessary in these patients, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer, but should be used with caution nonetheless.  Cardioselectivity is not absolute and can be lost with larger doses.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1143, 21513, 'Labetalol', 'Asthma', 'Some beta-adrenergic receptor blocking agents (i.e., non-cardioselective beta-blockers) are contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease.  In general, beta-adrenergic receptor blocking agents should not be used in patients with bronchospastic diseases.  Beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  If beta-blocker therapy is necessary in these patients, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer, but should be used with caution nonetheless.  Cardioselectivity is not absolute and can be lost with larger doses.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1144, 4696, 'Labetalol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1145, 7023, 'Labetalol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1146, 21511, 'Labetalol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1147, 21513, 'Labetalol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1148, 4696, 'Labetalol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1149, 7023, 'Labetalol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1150, 21511, 'Labetalol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1151, 21513, 'Labetalol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1152, 4696, 'Labetalol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1153, 7023, 'Labetalol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1154, 21511, 'Labetalol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1155, 21513, 'Labetalol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1156, 4696, 'Labetalol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1157, 7023, 'Labetalol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1158, 21511, 'Labetalol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1159, 21513, 'Labetalol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1160, 4696, 'Labetalol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1161, 7023, 'Labetalol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1162, 21511, 'Labetalol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1163, 21513, 'Labetalol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1164, 4696, 'Labetalol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1165, 7023, 'Labetalol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1166, 21511, 'Labetalol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1167, 21513, 'Labetalol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1168, 4696, 'Labetalol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1169, 7023, 'Labetalol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1170, 21511, 'Labetalol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1171, 21513, 'Labetalol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1172, 4696, 'Labetalol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1173, 7023, 'Labetalol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1174, 21511, 'Labetalol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1175, 21513, 'Labetalol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1176, 4696, 'Labetalol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1177, 7023, 'Labetalol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1178, 21511, 'Labetalol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1179, 21513, 'Labetalol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1180, 0, 'Ixekizumab', 'Infections', 'Upper respiratory tract infections, oral candidiasis, conjunctivitis, and tinea infections have occurred with the use of ixekizumab.  Close monitoring or discontinuation of therapy is recommended in patients with serious infections that do not respond to conventional treatment.  It is recommended to restart therapy only until the infection resolves.', '2', '"Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1181, 0, 'Ixekizumab', 'Inflammatory Bowel Diseases', 'Crohn''s disease and ulcerative colitis, including exacerbations have occurred during ixekizumab treatment.  Caution and close monitoring for onset or exacerbation of inflammatory bowel disease are recommended.', '2', '"Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1182, 0, 'Ixekizumab', 'Tuberculosis', 'Patients should be evaluated for tuberculosis (TB) infection prior to ixekizumab treatment.  It is recommended to initiate treatment of latent TB prior to administering ixekizumab and to consider anti-TB therapy prior to initiating therapy in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.  Do not administer this agent to patients with active TB infection.  Patients should be monitored closely for signs and symptoms of active TB during and after treatment.', '2', '"Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1183, 0, 'Ixekizumab', 'Liver Diseases', 'No formal clinical studies of the effect of hepatic or renal impairment on the pharmacokinetics of ixekizumab have been conducted.  Care should be taken when prescribing this drug to these patients.', '1', '"Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1184, 6795, 'Ketamine', 'Hypertension', 'The use of ketamine is contraindicated in patients whom a significant elevation of blood pressure would constitute a serious hazard.  It is recommended to monitor cardiac function continually during a procedure in patients with hypertension or cardiac decompensation.', '3', '"Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1185, 6864, 'Ketamine', 'Hypertension', 'The use of ketamine is contraindicated in patients whom a significant elevation of blood pressure would constitute a serious hazard.  It is recommended to monitor cardiac function continually during a procedure in patients with hypertension or cardiac decompensation.', '3', '"Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1186, 6865, 'Ketamine', 'Hypertension', 'The use of ketamine is contraindicated in patients whom a significant elevation of blood pressure would constitute a serious hazard.  It is recommended to monitor cardiac function continually during a procedure in patients with hypertension or cardiac decompensation.', '3', '"Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1187, 7331, 'Ketamine', 'Hypertension', 'The use of ketamine is contraindicated in patients whom a significant elevation of blood pressure would constitute a serious hazard.  It is recommended to monitor cardiac function continually during a procedure in patients with hypertension or cardiac decompensation.', '3', '"Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1188, 21359, 'Ketamine', 'Hypertension', 'The use of ketamine is contraindicated in patients whom a significant elevation of blood pressure would constitute a serious hazard.  It is recommended to monitor cardiac function continually during a procedure in patients with hypertension or cardiac decompensation.', '3', '"Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1189, 6795, 'Ketamine', 'Alcoholism', 'Ketamine should be used with caution in the chronic alcoholic and the acutely alcohol-intoxicated patient.', '2', '"Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1190, 6864, 'Ketamine', 'Alcoholism', 'Ketamine should be used with caution in the chronic alcoholic and the acutely alcohol-intoxicated patient.', '2', '"Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1191, 6865, 'Ketamine', 'Alcoholism', 'Ketamine should be used with caution in the chronic alcoholic and the acutely alcohol-intoxicated patient.', '2', '"Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1192, 7331, 'Ketamine', 'Alcoholism', 'Ketamine should be used with caution in the chronic alcoholic and the acutely alcohol-intoxicated patient.', '2', '"Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1193, 21359, 'Ketamine', 'Alcoholism', 'Ketamine should be used with caution in the chronic alcoholic and the acutely alcohol-intoxicated patient.', '2', '"Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1194, 3592, 'Kaolin', 'Intestinal Obstruction', 'The use of kaolin is contraindicated in patients with intestinal obstruction.', '3', '"Product Information. Kaolin-Pectin (kaolin-pectin)." Roxane Laboratories Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1195, 3592, 'Kaolin', 'Fever', 'Patients with diarrhea and fever should be seen by a physician.  The potential for the diarrhea to be associated with ulcerative colitis, Crohn''s disease, or amebiasis is increased in these patients.', '2', '"Product Information. Kaopectate (attapulgite)." Pharmacia and Upjohn  (2001):|"Product Information. Diasorb (attapulgite)." Columbia Laboratories Inc  (2001):|"Product Information. Donnagel (attapulgite)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1196, 23608, 'Ixazomib', 'Gastrointestinal Diseases', 'Ixazomib may cause diarrhea, constipation, nausea, and vomiting.  Care should be taken when using this agent in patients experiencing gastrointestinal complications.  It is recommended to adjust the dose of this agent as per the manufacturer dosing instructions for Grade 3 or 4 symptoms.  Evaluate for underlying causes and provide supportive care as necessary.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1197, 23609, 'Ixazomib', 'Gastrointestinal Diseases', 'Ixazomib may cause diarrhea, constipation, nausea, and vomiting.  Care should be taken when using this agent in patients experiencing gastrointestinal complications.  It is recommended to adjust the dose of this agent as per the manufacturer dosing instructions for Grade 3 or 4 symptoms.  Evaluate for underlying causes and provide supportive care as necessary.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1198, 23610, 'Ixazomib', 'Gastrointestinal Diseases', 'Ixazomib may cause diarrhea, constipation, nausea, and vomiting.  Care should be taken when using this agent in patients experiencing gastrointestinal complications.  It is recommended to adjust the dose of this agent as per the manufacturer dosing instructions for Grade 3 or 4 symptoms.  Evaluate for underlying causes and provide supportive care as necessary.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1199, 23608, 'Ixazomib', 'Hepatic Insufficiency', 'Pharmacokinetic studies of ixazomib in patients with moderate to severe hepatic impairment, showed an increase AUC when compared to patients with normal hepatic function.  The pharmacokinetic of ixazomib was similar in patients with normal hepatic function and in patients with mild hepatic impairment.  It is recommended to reduce the starting dose in patients with moderate to severe hepatic impairment.  Caution should be exercised when ixazomib is administered to patients with moderate to severe hepatic function and monitoring of liver function tests is recommended as appropriate.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1200, 23609, 'Ixazomib', 'Hepatic Insufficiency', 'Pharmacokinetic studies of ixazomib in patients with moderate to severe hepatic impairment, showed an increase AUC when compared to patients with normal hepatic function.  The pharmacokinetic of ixazomib was similar in patients with normal hepatic function and in patients with mild hepatic impairment.  It is recommended to reduce the starting dose in patients with moderate to severe hepatic impairment.  Caution should be exercised when ixazomib is administered to patients with moderate to severe hepatic function and monitoring of liver function tests is recommended as appropriate.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1201, 23610, 'Ixazomib', 'Hepatic Insufficiency', 'Pharmacokinetic studies of ixazomib in patients with moderate to severe hepatic impairment, showed an increase AUC when compared to patients with normal hepatic function.  The pharmacokinetic of ixazomib was similar in patients with normal hepatic function and in patients with mild hepatic impairment.  It is recommended to reduce the starting dose in patients with moderate to severe hepatic impairment.  Caution should be exercised when ixazomib is administered to patients with moderate to severe hepatic function and monitoring of liver function tests is recommended as appropriate.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1202, 23608, 'Ixazomib', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of ixazomib.  Patients should be monitored for symptoms of neuropathy and if they are experiencing new or worsening peripheral neuropathy, it is recommended to withhold therapy and modify the dose as per manufacturer instructions.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1203, 23609, 'Ixazomib', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of ixazomib.  Patients should be monitored for symptoms of neuropathy and if they are experiencing new or worsening peripheral neuropathy, it is recommended to withhold therapy and modify the dose as per manufacturer instructions.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1204, 23610, 'Ixazomib', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of ixazomib.  Patients should be monitored for symptoms of neuropathy and if they are experiencing new or worsening peripheral neuropathy, it is recommended to withhold therapy and modify the dose as per manufacturer instructions.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1205, 23608, 'Ixazomib', 'Kidney Diseases', 'Population PK analysis in patients with severe renal impairment or ESRD requiring dialysis showed an increase AUC when compared to patients with normal renal function.  The pharmacokinetic of ixazomib was similar in patients with normal renal function and in patients with mild or moderate renal impairment.  It is recommended to reduce the starting dose in patients with severe renal impairment or ESRD requiring dialysis.  Caution should be exercised when ixazomib is administered to patients with severe renal impairment.  Ixazomib is not dialyzable and therefore can be administered without regard to the timing of dialysis', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1206, 23609, 'Ixazomib', 'Kidney Diseases', 'Population PK analysis in patients with severe renal impairment or ESRD requiring dialysis showed an increase AUC when compared to patients with normal renal function.  The pharmacokinetic of ixazomib was similar in patients with normal renal function and in patients with mild or moderate renal impairment.  It is recommended to reduce the starting dose in patients with severe renal impairment or ESRD requiring dialysis.  Caution should be exercised when ixazomib is administered to patients with severe renal impairment.  Ixazomib is not dialyzable and therefore can be administered without regard to the timing of dialysis', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1207, 23610, 'Ixazomib', 'Kidney Diseases', 'Population PK analysis in patients with severe renal impairment or ESRD requiring dialysis showed an increase AUC when compared to patients with normal renal function.  The pharmacokinetic of ixazomib was similar in patients with normal renal function and in patients with mild or moderate renal impairment.  It is recommended to reduce the starting dose in patients with severe renal impairment or ESRD requiring dialysis.  Caution should be exercised when ixazomib is administered to patients with severe renal impairment.  Ixazomib is not dialyzable and therefore can be administered without regard to the timing of dialysis', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1208, 23608, 'Ixazomib', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of ixazomib.  It is recommended to monitor platelet counts regularly during treatment and to considered withholding therapy or dosage modifications and platelet transfusions as per manufacturer recommendations and clinical guidelines.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1209, 23609, 'Ixazomib', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of ixazomib.  It is recommended to monitor platelet counts regularly during treatment and to considered withholding therapy or dosage modifications and platelet transfusions as per manufacturer recommendations and clinical guidelines.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1210, 23610, 'Ixazomib', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of ixazomib.  It is recommended to monitor platelet counts regularly during treatment and to considered withholding therapy or dosage modifications and platelet transfusions as per manufacturer recommendations and clinical guidelines.', '2', '"Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1211, 3592, 'Kanamycin', 'Dehydration', 'Adequate hydration is crucial to minimize the risk of oto- and nephrotoxicity associated with the use of aminoglycosides.  Dehydration should preferably be corrected prior to initiation of therapy.  In patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting, fluid status should be monitored closely.  If signs of renal irritation develop during therapy, hydration should be increased as indicated, accompanied by a reduction in dosage if necessary.  Therapy should be withdrawn if urinary output decreases progressively or azotemia increases.', '3', '"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1212, 3592, 'Kanamycin', 'Neuromuscular Diseases', 'Aminoglycosides can cause dose-related neuromuscular blockade and muscle weakness, particularly in patients with neuromuscular disease or hypocalcemia and in patients receiving general anesthetics, neuromuscular blocking agents, or massive transfusions of citrate-anticoagulated blood.  Although aminoglycoside- induced neuromuscular blockade is generally self-limiting, it may rarely result in respiratory paralysis.  Neomycin is thought to be the most potent neuromuscular blocking agent in the class.  However, the risk is greatest with intraperitoneal or intrapleural instillation of large doses or rapid intravenous administration of parenteral aminoglycosides.  Therapy with aminoglycosides should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia.  If signs of respiratory paralysis occur during aminoglycoside therapy, the drug should be discontinued and mechanical respiratory assistance provided if necessary.', '3', 'Kaeser HE "Drug-induced myasthenic syndromes." Acta Neurol Scand 70 (1984):  39-47|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1213, 3592, 'Kanamycin', 'Ototoxicity', 'Aminoglycosides can cause eighth cranial nerve damage, resulting in vestibular and/or auditory toxicities.  Symptoms include dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Permanent hearing loss may occur, including, rarely, total or partial irreversible bilateral deafness after the drug has been discontinued.  Therapy with aminoglycosides, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Serial audiograms should be obtained in patients old enough to be tested, since loss of high- frequency perception usually precedes clinical hearing loss.  The dosage should be reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.', '3', 'Barza M, Lauermann MW, Tally FP, Gorbach SL "Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity." Antimicrob Agents Chemother 17 (1980):  707-14|Barza M, Lauermann MW, Tally FP, Gorbach SL "Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity." Antimicrob Agents Chemother 17 (1980):  707-14|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Danhauer FJ, Fortner CL, Schimpff SC, DeJongh CA, Wesley MN, Wiernik PH "Ototoxicity and pharmacokinetically determined dosages of amikacin in granulocytopenic cancer patients." Clin Pharm 1 (1982):  539-43|Uziel A "Non-genetic factors affecting hearing development." Acta Otolaryngol (Stockh) 421 (1985):  57-61|Lerner SA, Schmitt BA, Seligsohn R, Matz G "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin." Am J Med 80 Suppl 6 (1986):  98-104|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Bernstein JM, Gorse GJ, Linzmayer MI, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Smith CR, Lipsky JJ, Laskin OL, et al. "Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin." N Engl J Med 302 (1980):  1106-9|Tablan OC, Reyes MP, Rintelmann WF, Lerner AM "Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis." J Infect Dis 149 (1984):  257-63|Gatell JM, SanMiguel JG, Araujo V, et al. "Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin." Antimicrob Agents Chemother 26 (1984):  766-9|Bernstein JM, Gorse GJ, Linzmayer I, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Mathog RH, Klein WJ "Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia." N Engl J Med 280 (1969):  1223-4|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|Gailiunas P, Dominguez-Moreno M, Lazarus JM, et al. "Vestibular toxicity of gentamicin: incidence in patients receiving long-term hemodialysis therapy." Arch Intern Med 138 (1978):  1621-4|Deka RC, Ghosh P, Kacker SK "Streptomycin ototoxicity: an audiologic and vestibular study." Ear Nose Throat J 56 (1977):  218-24|Esterhai JL, Bednar J, Kimmelman CP "Gentamicin-induced ototoxicity complicating treatment of chronic osteomyelitis." Clin Orthop Aug (1986):  185-6|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|Gendeh BS, Said H, Gibb AG, Aziz NS, Kong N, Zahir ZM "Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis." J Laryngol Otol 107 (1993):  681-5|Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979):  309-19|Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978):  791-800|Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971):  359-63|Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973):  325-36|Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976):  561-70|Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973):  515-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Minor LB "Gentamicin-induced bilateral vestibular hypofunction." JAMA 279 (1998):  541-4|ElBakri F, Pallett A, Smith AG, Duncombe AS "Ototoxicity induced by once-daily gentamicin." Lancet 351 (1998):  1407-8|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1214, 3592, 'Kanamycin', 'Kidney Diseases', 'Aminoglycosides are potentially oto- and nephrotoxic.  Eighth cranial nerve damage may manifest as vestibular and/or auditory toxicities, including dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by tubular necrosis; increases in BUN, nonprotein nitrogen, and serum creatinine concentration; decreases in urine specific gravity and creatinine clearance; proteinuria; and cells or casts in the urine.  Rarely, renal electrolyte wasting may occur, resulting in hypocalcemia, hypomagnesemia, and hypokalemia that may be associated with paresthesia, tetany, confusion, and positive Chvostek and Trousseau signs.  Although aminoglycoside- induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred rarely.  Therapy with aminoglycosides should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.', '3', 'Beauchamp D, Gourde P, Theriault G, Bergeron MG "Age-dependent gentamicin experimental nephrotoxicity." J Pharmacol Exp Ther 260 (1992):  444-9|Dahlgren JG, Anderson ET, Hewitt WL "Gentamicin blood levels: a guide to nephrotoxicity." Antimicrob Agents Chemother 8 (1975):  58-62|Fanning WL, Gump D, Jick H "Gentamicin and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976):  80-2|Madhavan T, Yaremchuk K, Levin N, et al. "Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin." Antimicrob Agents Chemother 10 (1976):  464-5|Plantier J, Forrey AW, O''Neill MA, Blair AD, Christopher TG, Cutler RE "Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay." J Infect Dis 134 Suppl (1976):  s323-30|McHenry MC, Wagner JG, Hall PM, Vidt DG, Gavan TL "Pharmacokinetics of amikacin in patients with impaired renal function." J Infect Dis 134 Suppl (1976):  s343-54|Sarubbi FA, Hull JH "Amikacin serum concentrations: prediction of levels and dosage guidelines." Ann Intern Med 89 (1978):  612-8|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Lerner SA, Schmitt BA, Seligsohn R, Matz G "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin." Am J Med 80 Suppl 6 (1986):  98-104|Williams PJ, Hull JH, Sarubbi FA, Rogers JF, Wargin WA "Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin." J Clin Pharmacol 26 (1986):  79-86|Emanuelli G, Anfossi G, Calcamuggi G, Marcarino C, Lanzio M "Urinary enzyme release following aminoglycoside administration in single low dose." Enzyme 39 (1988):  119-22|Contreras AM, Gamba G, Cortes J, et al. "Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity." Antimicrob Agents Chemother 33 (1989):  973-6|French MA, Cerra FB, Plaut ME, Schentag JJ "Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients." Antimicrob Agents Chemother 19 (1981):  147-52|Pijck J, Hallynck T, Soep H, Baert L, Daniels R, Boelaert J "Pharmacokinetics of amikacin in patients with renal insufficiency: relation of half-life and creatinine clearance." J Infect Dis 134 (1976):  s331-41|Solberg CO, Madsen ST, Digranes A, et al. "High dose netilmicin therapy: efficacy, tolerance and tissue penetration." J Antimicrob Chemother 6 (1980):  133-41|Bhattacharya BK, Gorringe H, Farr MJ "Netilmicin and nephrotoxicity." Lancet 2 (1983):  216-7|Bergeron MG, Lessard C, Ronald A, Stiver G, Van Roogen CE, Chadwick P "Three to eight weeks of therapy with netilmicin: toxicity in normal and diabetic patients." J Antimicrob Chemother 12 (1983):  245-8|Bernstein JM, Gorse GJ, Linzmayer MI, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Matzke GR, Millikin, Kovarik JM "Variability in pharmacokinetic values for gentamicin, tobramycin, and netilmicin in patients with renal insufficiency." Clin Pharm 8 (1989):  800-6|Herrero A, Alarco FR, Diez JM, Mahiques E, Domingo JV "Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis." Int J Clin Pharmacol Ther Toxicol 26 (1988):  84-7|Craig WA, Gudmundsson S, Reich RM "Netilmicin sulfate: a comparative evaluation of antimicrobial activity, pharmacokinetics, adverse reactions and clinical efficacy." Pharmacotherapy 3 (1983):  305-15|Luft FC, Brannon DR, Stropes LL, Costello RJ, Sloan RS, Maxwell DR "Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis." Antimicrob Agents Chemother 14 (1978):  403-7|Humbert G, Leroy A, Fillastre JP, Oksenhendler G "Pharmacokinetics of netilmicin in the presence of normal or impaired renal function." Antimicrob Agents Chemother 14 (1978):  40-4|Russo ME, Atkin-Thor E "Gentamicin and ticarcillin in subjects with end-stage renal disease." Clin Nephrol 15 (1981):  175-80|Federspil P, Schatzle W, Tiesler E "Pharmacokinetics and ototoxicity of gentamicin, tobramycin and amikacin." J Infect Dis 134 (1976):  s200-5|Smith CR, Lipsky JJ, Laskin OL, et al. "Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin." N Engl J Med 302 (1980):  1106-9|Kumin GD "Clinical nephrotoxicity of tobramycin and gentamicin." JAMA 244 (1980):  1808-10|Keys TF, Kurtz SB, Jones JD, Muller SM "Renal toxicity during therapy with gentamicin or tobramycin." Mayo Clin Proc 56 (1981):  556-9|Schentag JJ, Cerra FB, Plaut ME "Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients." Antimicrob Agents Chemother 21 (1982):  721-6|Pines A, Goldhammer E, Kaplinsky N, Frankl O "Hypopotassemia associated with tobramycin treatment." Infection 10 (1982):  101-|Tablan OC, Reyes MP, Rintelmann WF, Lerner AM "Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis." J Infect Dis 149 (1984):  257-63|Watson AJ, Watson MM, Keogh JA "Metabolic abnormalities associated with tobramycin therapy." Isr J Med Sci 153 (1984):  96-9|Gatell JM, SanMiguel JG, Araujo V, et al. "Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin." Antimicrob Agents Chemother 26 (1984):  766-9|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Contrepois A, Brion N, Garaud JJ, et al. "Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans." Antimicrob Agents Chemother 27 (1985):  520-4|Wilkinson R, Lucas GL, Heath DA, et al. "Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides." Br Med J 292 (1986):  818-9|Pedersen SS, Jensen J, Osterhammel D, Osterhammel P "Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis." Antimicrob Agents Chemother 31 (1987):  594-9|Kunin CM, Finland M "Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin." J Clin Invest 38 (1959):  1509-19|Yoshikawa TT, Nagami PH "Adverse drug reactions in TB therapy: risks and recommendations." Geriatrics 37 (1982):  61-3, 67-8|Siegenthaler WE, Bonetti A, Luthy R "Aminoglycoside antibiotics in infectious diseases: an overview." Am J Med 80 (1986):  2-14|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|Trollfors B, Alestig K, Krantz I, Norrby R "Quantitative nephrotoxicity of gentamicin in nontoxic doses." J Infect Dis 141 (1980):  306-9|Letona JM, Barbolla L, Frieyro E, et al. "Immune haemolytic anaemia and renal failure induced by streptomycin." Br J Haematol 35 (1977):  561-71|McQueen EG "Antibiotic allergy and acute renal failure." N Z Med J 64 (1965):  561-3|Gyselnyck AM, Forrey A, Cutler R "Pharmacokinetics of gentamicin: distribution and plasma and renal clearance." J Infect Dis 124 (1971):  s70|Jaffe, Meyers BR, Hirschman SZ "Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis." Antimicrob Agents Chemother 5 (1974):  611-6|Schentag JJ, Lasezkay G, Cumbo TJ, et al. "Accumulation pharmacokinetics of tobramycin." Antimicrob Agents Chemother 13 (1978):  649-56|Pechere JC, Dugal R, Pechere MM "Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis." Clin Pharmacokinet 3 (1978):  395-406|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|Gilbert DN, Bennett WM "Use of antimicrobial agents in renal failure." Infect Dis Clin North Am 3 (1989):  517-31|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1215, 3592, 'Kanamycin', 'Intestinal Obstruction', 'The use of oral aminoglycosides is contraindicated in patients with intestinal obstruction.  Orally administered aminoglycosides are poorly absorbed from the gastrointestinal tract and primarily eliminated unchanged in the feces.  Drug retention and enhanced systemic absorption may occur in the presence of intestinal obstruction, increasing the risk of oto- and nephrotoxicity associated with these drugs.', '3', 'Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|"Product Information. Humatin (paromomycin)." Parke-Davis  (2001):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1216, 3592, 'Kanamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1217, 3182, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1218, 6867, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1219, 6868, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1220, 6869, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1221, 8908, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1222, 8914, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1223, 8916, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1224, 8919, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1225, 12764, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1226, 12765, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1227, 21326, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1228, 21481, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1229, 21482, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1230, 21483, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1231, 29644, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', 'Knight TE, Shikuma CY, Knight J "Ketoconazole-induced fulminant hepatitis necessitating liver transplantation." J Am Acad Dermatol 25 (1991):  398-400|Duarte PA, Chow CC, Simmons F, Ruskin J "Fatal hepatitis associated with ketoconazole therapy." Arch Intern Med 144 (1984):  1069-70|Lewis JH, Zimmerman HJ, Benson GD, Ishak KG "Hepatic injury associated with ketoconazole therapy: analysis of 33 cases." Gastroenterology 86 (1984):  503-13|Bercoff E, Bernuau J, Degott C, et al. "Ketoconazole-induced fulminant hepatitis." Gut 26 (1985):  636-8|Stricker BH, Blok AP, Bronkhorst FB, et al. "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases." J Hepatol 3 (1986):  399-406|Lake-Bakaar G, Scheuer PJ, Sherlock S "Hepatic reactions associated with ketoconazole in the United Kingdom." Br Med J (Clin Res Ed) 294 (1987):  419-22|van Parys G, Evenepoel C, van Damme B, Desmet VJ "Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship." Liver 7 (1987):  27-30|McCance DR, Ritchie CM, Sheridan B, Atkinson AB "Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole." Lancet Mar (1987):  573|Gradon JD, Sepkowitz DV "Massive hepatic enlargement with fatty change associated with ketoconazole." Ann Pharmacother 24 (1990):  1175-6|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):|Chien RN, Yang LJ, Lin PY, Liaw YF "Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study." Hepatology 25 (1997):  103-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1232, 3182, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1233, 6867, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1234, 6868, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1235, 6869, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1236, 8908, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1237, 8914, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1238, 8916, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1239, 8919, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1240, 12764, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1241, 12765, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1242, 21326, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1243, 21481, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1244, 21482, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1245, 21483, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1246, 29644, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1247, 3182, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1248, 6867, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1249, 6868, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1250, 6869, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1251, 8908, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1252, 8914, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1253, 8916, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1254, 8919, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1255, 12764, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1256, 12765, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1257, 21326, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1258, 21481, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1259, 21482, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1260, 21483, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1261, 29644, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', 'Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. "Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)." Ann Intern Med 109 (1988):  471-3|Mannisto PT, Mantyla R, Nykanen S, et al. "Impairing effect of food on ketoconazole absorption." Antimicrob Agents Chemother 21 (1982):  730-3|Daneshmend TK, Warnock DW, Ene MD, et al. "Influence of food on the pharmacokinetics of ketoconazole." Antimicrob Agents Chemother 25 (1984):  1-3|Daneshmend TK "Diseases and drugs but not food decrease ketoconazole "bioavailability"." Br J Clin Pharmacol 29 (1990):  783-4|"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1262, 3182, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1263, 6867, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1264, 6868, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1265, 6869, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1266, 8908, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1267, 8914, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1268, 8916, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1269, 8919, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1270, 12764, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1271, 12765, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1272, 21326, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1273, 21481, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1274, 21482, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1275, 21483, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1276, 29644, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1277, 0, 'Ivosidenib', 'Long QT Syndrome', 'Patients treated with ivosidenib can develop QTc prolongation and ventricular arrhythmias.  Concomitant use of ivosidenib with drugs known to prolong the QTc interval (e.g., antiarrhythmic medicines, fluoroquinolones, triazole antifungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation.  Conduct monitoring of electrocardiograms (ECGs) and electrolytes.  In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary.  Treatment should be interrupted or dose reduced if QTc increases to greater than 480 msec.  Permanently discontinue ivosidenib in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.', '2', '"Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Inc.  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1278, 0, 'Ivosidenib', 'Liver Failure', 'The pharmacokinetics of ivosidenib in patients with severe renal impairment (eGFR <30 mL/min/1.73m2,), renal impairment requiring dialysis, moderate hepatic impairment (total bilirubin 1.5 to 3.0 times the ULN and any value for AST), or severe hepatic impairment (total bilirubin greater than 3.0 times the ULN and any value for AST) is unknown.  Caution is advised if using in these patients.', '2', '"Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Inc.  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1279, 7040, 'Lactobacillus acidophilus', 'IMMUNE SUPPRESSION', 'Probiotics, especially those containing lactobacillus, should be used with caution in immunosuppressed patients.', '2', '"Product Information. Culturelle DS (lactobacillus rhamnosus GG)." ConAgra Functional Foods|Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis 35 (2002):  1155-60|Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK "Lactobacillus sepsis associated with probiotic therapy." Pediatrics 115 (2005):  178-81', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1280, 7486, 'Lactobacillus acidophilus', 'IMMUNE SUPPRESSION', 'Probiotics, especially those containing lactobacillus, should be used with caution in immunosuppressed patients.', '2', '"Product Information. Culturelle DS (lactobacillus rhamnosus GG)." ConAgra Functional Foods|Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis 35 (2002):  1155-60|Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK "Lactobacillus sepsis associated with probiotic therapy." Pediatrics 115 (2005):  178-81', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1281, 0, 'Abacavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1282, 0, 'Abacavir', 'Cardiovascular Diseases', 'Some clinical trials have reported increased risk of myocardial infarction in patients treated with abacavir.  Although some of the findings are inconclusive, as a precaution, the underlying risk of coronary heart disease should be assessed before therapy, and action should be taken to minimize all modifiable risk factors such as hypertension, hyperlipidemia, diabetes mellitus, smoking, etc.', '2', '"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1283, 0, 'Ixabepilone', 'Pancytopenia', 'Ixabepilone is contraindicated in patients who have a neutrophil count <1500 cells/mm3 or a platelet count <100,000 cells/mm3.', '3', '"Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1284, 0, 'Ixabepilone', 'Liver Diseases', 'The use of ixabepilone in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death.', '3', '"Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1285, 0, 'Ixabepilone', 'Cardiovascular Diseases', 'The use of ixabepilone in combination with capecitabine may increase cardiac adverse reactions, such as myocardial ischemia and ventricular dysfunction.  Care should be exercised when using this agent in combination with capecitabine in patients with a history of cardiac disease.  It is recommended to discontinue treatment in patients who develop cardiac ischemia or impaired cardiac function.', '2', '"Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1286, 0, 'Ixabepilone', 'Peripheral Nervous System Diseases', 'The use of ixabepilone in combination with capecitabine may cause peripheral neuropathy.  Patients treated with ixabepilone in combination with capecitabine should be monitored for symptoms of neuropathy.  Patients experiencing new or worsening symptoms may require a reduction or delay in the dose.  Caution should be used when treating patients with diabetes mellitus or preexisting peripheral neuropathy.', '2', '"Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1287, 0, 'Antihemophilic factor, human recombinant', 'Cardiovascular Diseases', 'Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with factor VIII.  Care should be exercised when using this agent in patients with cardiovascular risk factors.', '2', '"Product Information. Helixate FS (antihemophilic factor)." CSL Behring LLC  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1288, 0, 'Antihemophilic factor, human recombinant', 'Anemia, Hemolytic', 'Blood group isoagglutinins (anti-A and anti-B) are present in antihemophilic factor (human) at concentrations that may not be clinically significant when used to control minor bleeds.  Monitoring of hematocrit and Coombs for signs of intravascular hemolysis and falling hematocrit is recommended in patients with blood groups A, B, or AB when large or frequently repeated doses of antihemophilic factor (human) are administered.  Acute hemolytic anemia may occur, resulting in increased bleeding tendency or hyperfibrinogenemia.  Should this condition occur, leading to progressive hemolytic anemia, discontinue treatment and consider administering serologically compatible Type O red blood cells and providing alternative therapy.', '2', '"Product Information. Koate-HP (antihemophilic factor)." Bayer  (2001):|"Product Information. Humate-P (antihemophilic factor-von Willebrand factor)." CSL Behring LLC  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1289, 0, 'Antihemophilic factor, human recombinant', 'Immune Deficiency Disease', 'Because antihemophilic factor (human) is made from human blood, it may carry a risk of transmitting infectious agents.  The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses during the manufacturing process.  The risk of transmission of infectious agents cannot be eliminated completely.  Some viruses, such as Parvovirus B19 virus (B19V) or hepatitis A (HAV), are particularly difficult to remove or inactivate.  B19V may most seriously affect pregnant women and immune-compromised individuals.  Physicians should be alert to the potential symptoms of B19V and HAV infections and should strongly consider administration of hepatitis A and hepatitis B vaccines to individuals receiving plasma derivatives.  Potential risks and benefits of vaccination should be weighed by the physician and discussed with the patient.', '2', '"Product Information. Koate-HP (antihemophilic factor)." Bayer  (2001):|"Product Information. Humate-P (antihemophilic factor-von Willebrand factor)." CSL Behring LLC  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1290, 0, 'Antihemophilic factor, human recombinant', 'Thromboembolism', 'Thromboembolic events have been reported in patients receiving antihemophilic factor/von Willebrand factor complex replacement therapy.  Care should be exercised in the existence of known risk factors for thrombosis.  Endogenous high levels of factor VIII have also been associated with thrombosis, but no causal relationship has been established.  Caution is recommended and consider antithrombotic measures in all patients at risk who are receiving coagulation factor replacement therapy.', '2', '"Product Information. Koate-HP (antihemophilic factor)." Bayer  (2001):|"Product Information. Humate-P (antihemophilic factor-von Willebrand factor)." CSL Behring LLC  (2022):|"Product Information. Helixate FS (antihemophilic factor)." CSL Behring LLC  (2009):|"Product Information. Xyntha (antihemophilic factor)." Wyeth Laboratories  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1291, 3008, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1292, 3010, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1293, 3011, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1294, 4022, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1295, 4024, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1296, 4032, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1297, 7074, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1298, 7075, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1299, 7088, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1300, 7089, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1301, 7090, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1302, 7091, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1303, 7114, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1304, 7206, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1305, 21509, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1306, 21510, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1307, 21560, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1308, 21561, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1309, 21583, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1310, 21616, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1311, 21710, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1312, 26360, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Depakene (valproic acid)." Abbott Pharmaceutical  (2001):|"Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical  (2001):|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical  (2001):|"Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):|"Product Information. Vimpat (lacosamide)." UCB Pharma Inc  (2008):|"Product Information. Banzel (rufinamide)." Eisai Inc  (2008):|"Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1313, 3008, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1314, 3010, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1315, 3011, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1316, 4022, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1317, 4024, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1318, 4032, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1319, 7074, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1320, 7075, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1321, 7088, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1322, 7089, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1323, 7090, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1324, 7091, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1325, 7114, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1326, 7206, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1327, 21509, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1328, 21510, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1329, 21560, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1330, 21561, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1331, 21583, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1332, 21616, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1333, 21710, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1334, 26360, 'Lamotrigine', 'Exanthema', 'Severe, potentially fatal reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been associated with the use of lamotrigine.  The incidence has been reported at approximately 1 in 1000 for adults and up to 1 in 50 for pediatric patients treated with the drug.  Life-threatening rashes have usually, but not always, occurred within 2 to 8 weeks of initiating treatment.  Therapy with lamotrigine should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to lamotrigine.  Lamotrigine therapy should be withdrawn promptly at the first sign of a rash.  However, discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.  There have been suggestions that the risk of rash may be increased by 1) coadministration with valproic acid, 2) exceeding the recommended initial dosage, or 3) exceeding the recommended rate of dosage escalation of lamotrigine.', '3', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Wadelius M, Karlsson T, Wadelius C "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1041|Chaffin JJ, Davis SM "Suspected lamotrigine-induced toxic epidermal necrolysis." Ann Pharmacother 31 (1997):  720-3|Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996):  1597|Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998):  392-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1335, 3008, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1336, 3010, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1337, 3011, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1338, 4022, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1339, 4024, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1340, 4032, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1341, 7074, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1342, 7075, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1343, 7088, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1344, 7089, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1345, 7090, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1346, 7091, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1347, 7114, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1348, 7206, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1349, 21509, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1350, 21510, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1351, 21560, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1352, 21561, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1353, 21583, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1354, 21616, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1355, 21710, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1356, 26360, 'Lamotrigine', 'Hematologic Diseases', 'Reports of blood dyscrasias that may or may not be associated with multi-organ hypersensitivity (also known as DRESS) have been reported in patients treated with lamotrigine.  These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1357, 3008, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1358, 3010, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1359, 3011, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1360, 4022, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1361, 4024, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1362, 4032, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1363, 7074, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1364, 7075, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1365, 7088, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1366, 7089, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1367, 7090, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1368, 7091, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1369, 7114, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1370, 7206, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1371, 21509, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1372, 21510, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1373, 21560, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1374, 21561, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1375, 21583, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1376, 21616, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1377, 21710, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1378, 26360, 'Lamotrigine', 'Heart Diseases', 'Lamotrigine may slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with structural heart disease or myocardial ischemia.  In vitro studies have shown Class IB antiarrhythmic activity at therapeutically relevant concentrations.  Clinical studies have not shown antiarrhythmic activity in healthy individuals, but because of the risk of proarrhythmia, including sudden death, lamotrigine should not be used in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|"Product Information. LaMICtal XR (lamotrigine)." GlaxoSmithKline  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1379, 3008, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1380, 3010, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1381, 3011, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1382, 4022, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1383, 4024, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1384, 4032, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1385, 7074, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1386, 7075, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1387, 7088, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1388, 7089, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1389, 7090, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1390, 7091, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1391, 7114, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1392, 7206, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1393, 21509, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1394, 21510, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1395, 21560, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1396, 21561, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1397, 21583, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1398, 21616, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1399, 21710, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1400, 26360, 'Lamotrigine', 'Meningitis', 'Therapy with lamotrigine increases the risk of aseptic meningitis.  Symptoms upon presentation included headache, fever, nausea, vomiting, and nuchal rigidity and usually occurred after treatment initiation.  In most cases, symptoms resolved after discontinuation of treatment but returned quickly and more severely with reexposure.  Some of the patients who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus and other autoimmune diseases.', '2', '"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1401, 3008, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1402, 3010, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1403, 3011, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1404, 4022, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1405, 4024, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1406, 4032, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1407, 7074, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1408, 7075, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1409, 7088, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1410, 7089, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1411, 7090, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1412, 7091, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1413, 7114, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1414, 7206, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1415, 21509, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1416, 21510, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1417, 21560, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1418, 21561, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1419, 21583, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1420, 21616, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1421, 21710, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1422, 26360, 'Lamotrigine', 'Liver Diseases', 'Lamotrigine is primarily converted by the liver to inactive glucuronide metabolites and subsequently eliminated by the kidney.  Approximately 10% of a dose is excreted in the urine as unchanged drug.  The plasma clearance of lamotrigine may be decreased and the half-life prolonged in patients with impaired renal and/or hepatic function.  However, clinical data are limited.  In a comparison of 12 healthy subjects and 24 with various degrees of liver disease, lamotrigine pharmacokinetics were significantly altered only in patients with severe cirrhosis.  Therapy with lamotrigine should be administered cautiously and at reduced dosages in such patients.', '2', 'Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW "Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans." Clin Pharmacol Ther 42 (1987):  535-41|Peck AW "Clinical pharmacology of lamotrigine." Epilepsia 32 Suppl 2 (1991):  s9-12|Posner J, Cohen AF, Land G, Winton C, Peck AW "The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert''s syndrome)." Br J Clin Pharmacol 28 (1989):  117-20|Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, Seaman CA, Sheridan PH, Ashworth M, Kupferberg H, Valakas A, et al. "Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures." Clin Neuropharmacol 12 (1989):  312-21|Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E "Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis." Drugs Exp Clin Res 19 (1993):  25-32|"Product Information. Lamictal (lamotrigine)." Glaxo Wellcome  (2001):|Marcellin P, de Bony F, Garret C, et al. "Influence of cirrhosis on lamotrigine pharmacokinetics." Br J Clin Pharmacol 51 (2001):  410-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1423, 3008, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1424, 3010, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1425, 3011, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1426, 4022, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1427, 4024, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1428, 4032, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1429, 7074, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1430, 7075, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1431, 7088, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1432, 7089, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1433, 7090, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1434, 7091, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1435, 7114, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1436, 7206, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1437, 21509, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1438, 21510, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1439, 21560, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1440, 21561, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1441, 21583, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1442, 21616, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1443, 21710, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1444, 26360, 'Lamotrigine', 'Phenylketonurias', 'Lamotrigine tablets for oral suspension (chewable dispersible tablets) contain phenylalanine.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1445, 7051, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1446, 7061, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1447, 10242, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1448, 17961, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1449, 17962, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1450, 18804, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1451, 21541, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1452, 21545, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1453, 21547, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1454, 21551, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1455, 21655, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1456, 21656, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1457, 26675, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1458, 29352, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1459, 29353, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1460, 33077, 'Lactulose', 'Galactosemias', 'Since lactulose solution contains galactose, use is contraindicated in patients who require a low galactose diet.', '3', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1461, 7051, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1462, 7061, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1463, 10242, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1464, 17961, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1465, 17962, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1466, 18804, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1467, 21541, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1468, 21545, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1469, 21547, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1470, 21551, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1471, 21655, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1472, 21656, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1473, 26675, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1474, 29352, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1475, 29353, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1476, 33077, 'Lactulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1477, 7051, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1478, 7061, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1479, 10242, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1480, 17961, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1481, 17962, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1482, 18804, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1483, 21541, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1484, 21545, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1485, 21547, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1486, 21551, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1487, 21655, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1488, 21656, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1489, 26675, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1490, 29352, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1491, 29353, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1492, 33077, 'Lactulose', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1493, 7051, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1494, 7061, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1495, 10242, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1496, 17961, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1497, 17962, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1498, 18804, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1499, 21541, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1500, 21545, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
